Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Conference Call March 20, 2024 4:30 PM ET

Company Participants

Kiki Patel - Gilmartin Group LLC
Talat Imran - Chief Executive Officer
Arvinder Dhalla - Vice President, Clinical Development
Svai Sanford - Chief Financial Officer

Conference Call Participants

Olivia Brayer - Cantor Fitzgerald
Edward Nash - Canaccord Genuity
Julian Harrison - BTIG
John Vandermosten - Zacks

Operator

Welcome to Rani Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are a in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ensure that we have ample time to address everyone's questions during the Q&A session, we would ask for a limit of one question and one follow-up question per person. [Operator Instructions] As a reminder, this call is being recorded today Wednesday, March 20, 2024.

I would now like to turn the conference call over to Kiki Patel at Gilmartin Group. Please go ahead.

Kiki Patel

Thank you, operator. Joining us on the call today from Rani Therapeutics' are Chief Executive Officer, Talat Imran; VP of Clinical Development, Arvinder Dhalla, and Chief Financial Officer, Svai Sanford.

During this conference call, management will make forward-looking statements that are subject to risks, uncertainties and assumptions such as but not limited to, those discussed in the risk factor section of the company's filings with the Securities and Exchange Commission including its annual report on Form 10-K and quarterly reports on Form 10-Q, which identify the specific factors that may cause actual events or results differ materially from those described in these forward-looking statements.

These things may include without limitation statements regarding product development and clinical trials, product potential, market sizes, platform progress, platform potential, certain business strategies, capital resources financing plans or operating performance. Actual results and the timing of events could differ materially from those projected in such forward-looking statements.

With that, I'll turn the call over to Talat Imran, Chief Executive Officer of Rani Therapeutics. Talat?

Talat Imran

Thank you. I'm delighted to share the highlights of Rani Therapeutics' strong performance in 2023 during which the company achieved numerous milestones in the development of its pipeline programs and high capacity oral delivery device.

Rani Therapeutics is a clinical stage biotech company that has developed a platform technology for the oral administration of biologics with bioavailability comparable to a subcutaneous injection. The RaniPill platform is designed to address any therapeutic area where biologics are used. Our current focus is on immunology and endocrinology, with discovery efforts underway in obesity and other therapeutic areas and drug modalities.